NEW YORK (GenomeWeb News) – HTG Molecular Diagnostics and OvaGene Oncology today announced a manufacturing supply agreement for the design and development of gene expression assays for gynecologic cancers on HTG's platform.

Under the terms of the deal, OvaGene will develop the assays on the HTG Edge System, an automated gene expression platform that delivers multiplexed results on lysed samples in less than one day. HTG launched the platform in 2013 with a portfolio of mRNA assays based on the company's proprietary nuclease protection chemistry.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genes under positive selection in Plasmodium falciparum populations, genetic variation in Epstein-Barr viruses, and more.

Cancer clinical trial patients settle with Anil Potti and Duke University.

A trio of researchers is trying to raise money to sequence and analyze the genome of a cat with a suite of unusual traits.

Two Johns Hopkins researchers discuss the need for evidence-based data analysis.